-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The effect of infection toxicity with low methylating agents (HMAs) on overall survival (OS) in patients diagnosed with high-risk bone marrow tumors has not been thoroughly investigated
The researchers obtained data from 412 unselected serial patients in 23 Spanish hospitals who were diagnosed with high-risk myelodysplastic syndrome, chronic monocytic leukemia or acute myeloid leukemia and received HMA treatment
The results suggest that the infection rate is 1.
Figure 1.
In multivariate assays, factors associated with the lower OS had any infection in the first four cycles (risk ratio (HR) = 1.
Figure 2.
BM blast cells > 20% (HR = 1.
Overall, HMA infection toxicity is thought to exacerbate OS, hinder adherence to antineoplastic therapy, and lead to significant morbidity
Original Source:
Vilorio-Marqués L, Castañón Fernández C, Mora E, Gutiérrez L, Rey Bua B, Jiménez Lorenzo MJ, Díaz Beya M, Vara Pampliega M, Molero A, Sánchez-García J, Calabuig M, Cedena MT, Chen-Liang T, Díaz Santa JA, Padilla I, Hernández F, Díez R, Asensi P, Xicoy B, Sanz G, Valcárcel D, Diez-Campelo M, Bernal T.
